News

To date, 2,007 mutations have been identified in the CFTR gene, but their contribution for cystic fibrosis (CF) development has not been defined for the majority of these mutations. Now, researchers at Children’s Hospital Los Angeles and the Genetic Disease Screening Program of the California Department of Public Health have…

Alcresta Therapeutics recently launched the commercialization of the digestive enzyme cartridge Relizorb to help patients unable of breaking down fats, particularly adults with cystic fibrosis (CF) who depend on enteral nutrition. Cystic fibrosis is a life-threatening genetic condition caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene…

Vertex Pharmaceuticals recently revealed new clinical data on real-world long-term outcomes in cystic fibrosis (CF) patients treated with Kalydeco (ivacaftor). The company also presented data from a Phase 3 study evaluating Orkambi (lumacaftor/ivacaftor) for children with CF ages 6-11 years. The results were available June 11-14 at the 39th European Cystic Fibrosis Society (ECFS)…

Raptor Pharmaceutical recently announced new clinical data from a Phase 3 trial evaluating the efficacy of Quinsair (levofloxacin) versus tobramycin in cystic fibrosis (CF) patients with chronic pulmonary infections caused by Pseudomonas aeruginosa. Study results were presented at the 39th European Cystic Fibrosis Conference in Basel, Switzerland. “Patients with cystic fibrosis have few…

TGV-inhalonix reported clinical findings at the European Cystic Fibrosis Conference recently Basel, Switzerland, that show the potential of a new drug to treat mixed bacterial and fungal lung infections contracted by patients with cystic fibrosis (CF). The data presented by George Tetz, scientific and development advisor of TGV-inhalonix, indicated that Mul-1867…

Researchers at the University of Iowa have uncovered a link between the dysfunction of cystic fibrosis protein CFTR and airway smooth muscle (ASM) abnormalities — two common pathologies of the chronic lung disorder cystic fibrosis (CF). The study, “Acute administration of ivacaftor to people with cystic fibrosis and a…

Swiss Pharmaceutical company Polyphor has successfully completed its Phase I clinical trial in healthy volunteers for the investigational inhaled POL6014. POL6014 is a selective and reversible inhibitor of human neutrophil elastase (hNE), a key target for the treatment of respiratory diseases like cystic fibrosis (CF). Cystic fibrosis is a genetic…

The Boomer Esiason Foundation (BEF), a partnership of medical and business leaders dedicated to increasing awareness, education, and quality of life for people living with cystic fibrosis (CF), recently announced the premiere of the documentary “Up for Air” on June 20 in a private screening in New York City. The documentary follows…

Healthcare workers with cystic fibrosis (CF) are more likely to contract methicillin-resistant staphylococcus aureus (MRSA) infections than CF patients not in healthcare scenarios, according to the study “Methicillin-resistant Staphylococcus aureus acquisition in healthcare workers with cystic fibrosis: a retrospective cross-sectional study,” published in BMC Pulmonary Medicine. MRSA infection is caused…

A new study from the University of Iowa might show that an old drug can be used in a new way: to treat cystic fibrosis airway disease. The research report, “Repurposing tromethamine as inhaled therapy to treat CF airway disease,“ appeared in the scientific journal…